Life Sciences

The modern therapeutic landscape is defined by an ever-growing portfolio of complex drug products – from biologics and gene therapies to mRNA-based vaccines and monoclonal antibodies. These therapies, which often involve intricate fomulations and require advanced sterile processing, have fundamentally altered the demands placed on fill-finish operations. Frank Tagliaferri, chief scientific officer at Pace® Life […]

Company expands sterile fill-finish services, capacity for biologics development and manufacturing, and more. Minneapolis, MN – January 10, 2025 – Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, today announced significant growth plans for two of the company’s locations. Pace® Life

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration. Despite their track record of demonstrating significant therapeutic efficacy, biologics still face daunting challenges in their drug delivery. Biologics such as monoclonal antibodies (mAbs) and some vaccines are largely administered via injection or by infusion. These methods can often